|
Baroja-Mazo A, Pelegrín P. Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates. J Osteoporos. 2012;2012:408242. doi: 10.1155/2012/408242. Epub 2012 Jul 8. PubMed PMID: 22830074; PubMed Central PMCID: PMC3399340.
AÑO: 2012
|
22830074
|
Lopez-Castejón G, Baroja-Mazo A, Pelegrín P. Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules. Cell Mol Life Sci. 2011 Sep;68(18):3095-107. doi: 10.1007/s00018-010-0609-y. Epub 2010 Dec 28. PubMed PMID: 21188461.
AÑO: 2011; IF: 6.496
|
|
Jelassi B, Chantôme A, Alcaraz-Pérez F, Baroja-Mazo A, Cayuela ML, Pelegrin P, Surprenant A, Roger S. P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011 May 5;30(18):2108-22. doi: 10.1038/onc.2010.593. Epub 2011 Jan 17. PubMed PMID: 21242969.
AÑO: 2011; IF: 6.373
|
|
Pelegrín P. Many ways to dilate the P2X7 receptor pore. Br J Pharmacol. 2011 Jul;163(5):908-11. doi: 10.1111/j.1476-5381.2011.01325.x. PubMed PMID: 21410461; PubMed Central PMCID: PMC3130938.
AÑO: 2011; IF: 4.409
|
|
Roger S, Pelegrin P. P2X7 receptor antagonism in the treatment of cancers. Expert Opin Investig Drugs. 2011 Jul;20(7):875-80. doi: 10.1517/13543784.2011.583918. Epub 2011 May 27. PubMed PMID: 21619470.
AÑO: 2011; IF: 5.274
|